Drug intelligence / Profile preview

astragalus + gemcitabine

Development stage: Unknown
Lead developer: Shenzhen University General Hospital
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

Astragalus + gemcitabine is an investigational combination therapy for the neoadjuvant treatment of pancreatic cancer. It combines Astragalus polysaccharide (APS), a traditional Chinese medicine preparation from *Astragalus membranaceus*, with the standard chemotherapy drug gemcitabine. APS is an immunomodulator and biologic agent that is believed to enhance anticancer immune responses, partly by modulating the PI3K/Akt/mTOR pathway. [14, 17, 18, 19] Clinical studies suggest that the combination therapy improves objective response rates, disease control rates, and median survival time in pancreatic cancer patients compared to gemcitabine alone, while also reducing chemotherapy-related side effects like leukopenia and fatigue.

Other names: Astragalus combined with Gemcitabine

Targets

PRR (Pattern recognition receptors)ABCB1 (P-glycoprotein)

Beyond the preview

Go deeper on astragalus + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on astragalus + gemcitabine.

Explore the full profile